Insulin Treatments

EDM number 535 in 2006-07, proposed by Sandra Gidley on 18/12/2006.

That this House congratulates Wockhardt Pharmaceuticals on the expansion of production facilities for animal insulins to cope with increased demand as a result of Novo Nordisk Pharmaceutical's discontinuation of their pork insulin and thanks the Minister of State, the hon. Member for Leigh, for his Department's role in ensuring that animal insulins continue to be available for those people who need them, but regrets that Novo Nordisk Pharmaceuticals has begun a systematic discontinuation of their synthetic `human' insulin products in favour of insulin analogues, further reducing patient and physician choice; expresses grave reservations that many patients are being transferred to insulin analogues before their long-term safety has been established and before studies recommended by the European Agency for the Evaluation of Medical Products have been carried out to investigate the potential for carcinogenic effects of insulin analogues; and therefore requests that the Secretary of State for Health asks the National Institute for Health and Clinical Excellence to assess the safety, clinical and cost effectiveness of all insulins to provide patients and clinicians with the necessary information to make informed treatment choices.

This motion has been signed by a total of 110 MPs, 2 of these signatures have been withdrawn.